Turn Therapeutics Posts New GX-03 Subgroup Data: 61.5% vs 8.3% vIGA Success at Week 4
TTRX has more than doubled off its 52-week low of $2.57.
Summary
Turn Therapeutics furnished an updated investor presentation with new PP-NRS≥7 subgroup data showing 61.5% vs 8.3% Week 4 vIGA-AD success and a Phase 2b design of N≈120-136. The deck also maps out 2027 trial starts against $10.4M of cash with runway into Q3 2027.
Key Events · Product Development and Regulatory · TTRX
-
New PP-NRS≥7 Subgroup Efficacy Data
In the PP-NRS≥7 subgroup (N=25), Week 4 vIGA-AD success was 61.5% for GX-03 versus 8.3% for vehicle (Δ53.2%, p≈0.0123), and Week 4 EASI-75 was 69.2% versus 25.0% (Δ44.2%, p≈0.0407).
-
Phase 2b Design Disclosed
Stage 2/Phase 2b enrolls N≈120-136 across three baseline-EASI strata, 1:1 randomized and vehicle-controlled, powered to ≥99.8%, with Week 4 vIGA-AD success as the anticipated registrational endpoint.
-
2027 Clinical Calendar Mapped
AD Phase 2 topline expected Q1 2027 with Phase 3 initiation mid-2027; HS Phase 2a initiation Q1 2027; onychomycosis Phase 3 initiation Q2 2027.
-
Cash Runway Into Q3 2027
$10.4M cash as of September 30, 2026 funds operations into Q3 2027, with ~30.5M shares outstanding and ~$1M/quarter G&A burn; later milestones require additional capital.
Analysis · TTRX · Life Sciences
The updated deck sharpens the GX-03 atopic dermatitis case with a PP-NRS≥7 enriched subgroup where Week 4 vIGA-AD success hit 61.5% for GX-03 versus 8.3% for vehicle (p≈0.0123) and Week 4 EASI-75 reached 69.2% versus 25.0% (p≈0.0407). That subgroup is the basis for the Phase 2b design now disclosed at N≈120-136, powered to ≥99.8%, with Week 4 vIGA-AD success framed as the anticipated registrational endpoint. The deck also lays out a fuller calendar — HS Phase 2a starting Q1 2027, onychomycosis Phase 3 in Q2 2027, AD Phase 3 mid-2027 — against $10.4M of cash and runway into Q3 2027, so the later milestones depend on raising capital. The Phase 2 topline readout expected Q1 2027 is the event that will test whether these subgroup numbers hold in a larger, stratified trial.
How filings like this one have moved
In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TTRX was trading at $9.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $298.9M. The 52-week trading range was $2.57 to $16.45. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.